Teplizumab rallenta la progressione del diabete tipo 1 di nuova insorgenza
Crossref DOI link: https://doi.org/10.1007/s40619-024-01475-y
Published Online: 2024-06-10
Published Print: 2024-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pieralice, Silvia
Buzzetti, Raffaella
Text and Data Mining valid from 2024-06-01
Version of Record valid from 2024-06-01
Article History
Accepted: 7 December 2023
First Online: 10 June 2024
Dichiarazioni etiche
:
: Gli Autori dichiarano di non avere conflitti di interesse.